About Shanghai Allist Pharmaceuticals Co., Ltd. Company

The company is headquartered in Zhoupu Medical Park in Shanghai. It was founded in March 2004 by entrepreneur Mr. Du Jinhao and Dr. Guo Jianhui, a US National Institutes of Health (NIH) lifelong scientist honor. It is an innovative pharmaceutical company integrating R&D, production and marketing. It is an innovative pharmaceutical company integrating R&D, production and marketing. It is guided by the unmet clinical needs of the global pharmaceutical market, and focuses on the field of tumor treatment, with the goal of developing pioneering drugs (First-in-class) and best-in-class drugs (Best-in-Class) It is committed to developing and producing innovative drugs with independent intellectual property rights, which are safe, effective, and beneficial to the public. After completing the A and A+ rounds of financing in 2019, it was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on December 2, 2020. The company is an innovative drug company focusing on the field of tumor treatment, and has now built an advantageous R&D pipeline in the field of targeted drugs for non-small cell lung cancer (NSCLC). The company's main products are vometinib mesylate tablets, golerese, and platinib capsules. Corporate honors: “Pharmaceutical Innovation Achievement Award of the Year”, “2020 Ji World Cup Top Ten Pharmaceutical Innovation Emerging Companies of the Year”, “Top 10 Best Biomedical Listed Companies”, and 2021 China Pharmaceutical Emerging Innovation Force Enterprise. The company won honorary titles such as “2020 World Cup Top Ten Pharmaceutical Innovation Emerging Companies” hosted by the Securities Times, “Top 10 Best Biomedical Listed Companies” in the 2020 China Healthcare Industry Investment and Financing Glory List, 2021 China Pharmaceutical Emerging Innovation Power Enterprise, etc., and also joined the “China Pharmaceutical Innovation Promotion Association Member”, “Pharmaceutical Innovation 100 Alliance Founding Board Member”, and “2022 Shanghai Top 100 Hard Core Enterprises”, and continues to demonstrate its hard-core strength. The chairman of the company, Mr. Du Jinhao, won the “EY Entrepreneur Of The Year Award” in 2022.